Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 GlobeNewswire - Wed Apr 8, 6:00AM CDT

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy GlobeNewswire - Tue Apr 7, 6:00AM CDT

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates  GlobeNewswire - Thu Mar 5, 6:00AM CST

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials...

CLYM : 8.97 (-2.07%)
Climb Bio to Present at Upcoming Investor Conferences GlobeNewswire - Thu Feb 5, 6:00AM CST

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 GlobeNewswire - Thu Jan 8, 6:00AM CST

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Nov 25, 2025

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 8.97 (-2.07%)
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Nov 6, 2025

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical...

CLYM : 8.97 (-2.07%)
Climb Bio to Present at Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 2025

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy GlobeNewswire - Tue Oct 21, 2025

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 8.97 (-2.07%)
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Wave Life Sciences (WVE) Tipranks - Fri Oct 17, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM – Research Report) and Wave Life Sciences (WVE – Research Report) with bullish sentiments.Elevate...

CLYM : 8.97 (-2.07%)
WVE : 7.58 (+1.20%)

Barchart Exclusives

As Costco Raises Its Dividend More Than 13%, Should You Buy, Sell, or Hold COST Stock? Barchart - Mon Apr 20, 6:30PM CDT
Costco raised its quarterly dividend 13.1% to $1.47 per share. Here's what investors need to know before deciding to buy, sell, or hold COST stock right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.